• Citer

Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.

par Kramer, J A;Curran, D.;Piccart-Gebhart, Martine ;de Haes, J C;Bruning, Peter;Klijn, J G;Bontenbal, M;van Pottelsberghe, C;Groenvold, M;Paridaens, R.
Référence European journal of cancer, 36, 12, page (1488-1497)
Publication Publié, 2000-08

Article révisé par les pairs

• Détails
• Contenu

Titre:	Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.
Auteur:	Kramer, J A; Curran, D.; Piccart-Gebhart, Martine; de Haes, J C; Bruning, Peter; Klijn, J G; Bontenbal, M; van Pottelsberghe, C; Groenvold, M; Paridaens, R.
Informations sur la publication:	European journal of cancer, 36, 12, page (1488-1497)
Statut de publication:	Publié, 2000-08
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Antineoplastic Agents -- therapeutic use
	Antineoplastic Agents, Phytogenic -- therapeutic use
	Bias (Epidemiology)
	Breast Neoplasms -- drug therapy
	Cross-Over Studies
	Disease-Free Survival
	Doxorubicin -- therapeutic use
	Female
	Humans
	Paclitaxel -- therapeutic use
	Patient Compliance
	Prospective Studies
	Quality of Life
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase II
	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:pii/S0959-8049(00)00134-9
	info:pmid/10930796